Neoadjuvant immunochemotherapy in locally advanced esophageal squamous cell carcinoma: a retrospective study with 2-year survival analysis
Journal of Cancer Research and Clinical Oncology · 17.07.2025 · 151 (7)
DOI: 10.1007/s00432-025-06263-1 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cancer Research and Clinical Oncology, online erschienen am 17.07.2025. Verfasst von Chong-Rui Li und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, The Second Hospital & Clinical Medical School, Lanzhou University, 82 Cuiyingmen, Chengguan District, Lanzhou, 730030…. Hauptthemen laut MEDLINE: Esophageal Squamous Cell Carcinoma, Neoadjuvant Therapy, Esophageal Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Science and Technology Key Research and Development Program of Gansu Province, Key Talent Project of Gansu Province, Special Fund for Clinical Research of Wu JiePing Medical Foundation.
Abstract (Originalsprache)
Background
Neoadjuvant immunochemotherapy (NICT) has shown encouraging short-term outcomes in patients with locally advanced resectable esophageal squamous cell carcinoma (ESCC), but data on long-term survival remain limited. This study compared the therapeutic efficacy, safety, and 2-year survival outcomes of NICT versus surgery alone.
Methods
We retrospectively analyzed patients with locally advanced resectable ESCC who underwent either NICT followed by surgery or upfront surgery alone. Primary endpoints were disease-free survival (DFS) and overall survival (OS).
Results
A total of 188 patients were included, with 60 receiving NICT and 128 undergoing surgery alone. The NICT group achieved better 2-year DFS (76.7% vs. 57.0%, P = 0.021) and OS (86.7% vs. 68.0%, P = 0.0053), with similar rates of postoperative complications (40.0% vs. 37.5%, P = 0.742). No ≥ grade 3 postoperative complications occurred in the NICT group, while three cases (2.3%) were observed in the surgery-alone group. Pathological responses to NICT included 28.3% complete response (pCR) and 61.7% major response (MPR). Grade 3 treatment-related adverse events occurred in 20.0% of NICT patients, with no grade ≥ 4 events. Patients achieving pCR or MPR had significantly better survival outcomes than non-responders. Survival outcomes were similar between 2-cycle and > 2-cycle NICT regimens. ECOG performance status, coronary artery disease, and treatment modality were identified as independent prognostic factors.
Conclusion
NICT followed by surgery demonstrated favorable pathological response and 2-year survival outcomes in locally advanced ESCC, supporting its potential as a neoadjuvant strategy pending further prospective validation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Thoracic Surgery, The Second Hospital & Clinical Medical School, Lanzhou University, 82 Cuiyingmen, Chengguan District, Lanzhou, 730030, Gansu Province, China.
- Department of Thoracic Surgery, The Second Hospital & Clinical Medical School, Lanzhou University, 82 Cuiyingmen, Chengguan District, Lanzhou, 730030, Gansu Province, China. leebin@lzu.edu.cn.
ORCID-Profile: Bin Li
Förderung
- Science and Technology Key Research and Development Program of Gansu Province
- Key Talent Project of Gansu Province
- Special Fund for Clinical Research of Wu JiePing Medical Foundation
Zitieren
APA
Li, C. R., Chen, Y. Z., Li, B., Ren, M. Y., Meng, Y. Q., Song, T. N., Yang, J. B., Wang, C., Wei, X. P., Jiang, P., & Zhu, D. J. (2025). Neoadjuvant immunochemotherapy in locally advanced esophageal squamous cell carcinoma: a retrospective study with 2-year survival analysis. Journal of Cancer Research and Clinical Oncology, 151(7). https://doi.org/10.1007/s00432-025-06263-1
Vancouver
Li CR, Chen YZ, Li B, Ren MY, Meng YQ, Song TN, et al. Neoadjuvant immunochemotherapy in locally advanced esophageal squamous cell carcinoma: a retrospective study with 2-year survival analysis. Journal of Cancer Research and Clinical Oncology. 2025;151(7). doi:10.1007/s00432-025-06263-1
BibTeX
@article{Li2025,
author = {Li, Chong-Rui and Chen, Yu-Zhen and Li, Bin and Ren, Mei-Yu and Meng, Yu-Qi and Song, Tie-Niu and Yang, Jian-Bao and Wang, Cheng and Wei, Xiao-Ping and Jiang, Peng and Zhu, Duo-Jie},
title = {Neoadjuvant immunochemotherapy in locally advanced esophageal squamous cell carcinoma: a retrospective study with 2-year survival analysis},
journal = {Journal of Cancer Research and Clinical Oncology},
year = {2025},
volume = {151},
number = {7},
doi = {10.1007/s00432-025-06263-1}
}
EUVIMED